Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 114. Отображено 100.
26-01-2017 дата публикации

CYCLOPAMINE ANALOGS

Номер: US20170022212A1
Принадлежит:

The invention provides derivatives of cyclopamine having the following formula: 2. The process of claim 1 , wherein Rand Rare both H.3. The process of claim 1 , wherein Ris a protected hydroxyl.4. The process of claim 1 , wherein Ris a nitrogen protecting group.6. The process of wherein Rand Rare each 2 claim 5 ,6-dimethylphenyl.9. The process of claim 8 , wherein Rand Rare both H.10. The process of claim 8 , wherein said protected hydroxyl group is an ester or a carbonate.11. The process of claim 8 , wherein said nitrogen protecting group is a carbamate.12. The process of claim 8 , wherein said nitrogen protecting group is an amide.13. The process of claim 8 , wherein Rand Rare H and Rand Rtaken together form a bond.14. The process of claim 8 , wherein said cyclopropanating agent is generated from a dihaloalkane and a metal species.15. The process of claim 14 , wherein said metal species is dialkyl zinc or a zinc copper couple.16. The process of claim 8 , wherein said cyclopropanating agent is generated from a dihaloalkane species and a dialkyl zinc species claim 8 , and a phosphoric acid species or a salt thereof.18. The process of claim 8 , wherein said acid is acetic acid claim 8 , trifluoromethanesulfonic acid claim 8 , phosphoric acid claim 8 , methanesulfonic acid or HCl.19. The process of claim 8 , wherein said acid is BF claim 8 , zinc chloride claim 8 , zinc methanesulfonate claim 8 , or a zinc salt.22. The process of claim 21 , wherein said oxygen protecting group is alkyl carbonate claim 21 , aralkyl carbonate claim 21 , benzoate claim 21 , pivaloate claim 21 , or formate.23. The process of claim 21 , wherein said nitrogen protecting group is benzoyl claim 21 , trichloroacetyl claim 21 , trifluoroacetyl claim 21 , formyl claim 21 , alkyl carbamates claim 21 , aralkyl carbamates claim 21 , or aryl carbamates.24. The process of claim 21 , wherein said oxygen protecting group is benzylcarbonate.25. The process of claim 21 , wherein said nitrogen protecting ...

Подробнее
18-02-2021 дата публикации

Crystal forms of an antitumor agent and their preparation methods

Номер: US20210047362A1
Автор: Gong Xianchang
Принадлежит:

The present invention provides two crystal forms of jervine and their preparation methods, and their application as antitumor agents. The preparation methods of these two crystal forms are simple, high yield and can be easily scaled to industry scale. 2. The crystal form I of claim 1 , wherein the characteristic peaks represented by 2 θ angle (±0.2°) are positioned at 6.7399° 8.7103° 10.9690° 11.0651° 12.1224° 15.0048° 16.1113° 20.2443° 20.6768° 23.1278° 26.2035° 27.1966° 27.6453° 41.0536° in the X-ray powder diffraction pattern.3. The crystal form of claim 1 , wherein the X-ray powder diffraction pattern of crystal form I is shown in .4. A preparation method for the crystal form I of claim 1 , comprise the following steps:(1) Jervine is mixed with menthanol at room temperature for a clear solution;(2) remove menthanol till solid start to precipitate, filter to obtain crystal form I.5. A pharmaceutical agent claim 1 , wherein the agent contains a therapeutically effective amount of crystal form I of and a pharmaceutically acceptable carrier and/or an excipient.6. The present invention provides crystal form II of jervine claim 1 , wherein the characteristic peaks represented by 2 θ angle (±0.20) are positioned at 13.6199° 13.3548° 14.6803° 15.0188° 14.4729° 20.7405° 20.9599° 17.1282° 8.8458° 16.3034° in the X-ray powder diffraction pattern.7. The crystal form II of claim 6 , wherein the characteristic peaks represented by 2 θ angle (±0.2) are positioned at 16.0515° 19.7802° 15.8398° 9.1034° 11.6825° 21.2135° 20.4846° 17.7607° 20.2196° 26.0347° 23.3938° 25.7750° 24.0115° 18.2995° 44.4657° 27.4530° 31.6225° 35.6230° 30.7323° 26.3009° 42.2070° in the X-ray powder diffraction pattern.86. The crystal form of chain claim 6 , wherein the X-ray powder diffraction pattern of crystal form II is shown in .9. A preparation method for the crystal form II of claim 6 , comprise the following steps:(1) Jervine is mixed with acetonitrile at room temperature for a clear solution;(2) ...

Подробнее
05-04-2018 дата публикации

COMPOUND FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTION AND PREPARATION METHOD AND USE THEREOF

Номер: US20180094021A1
Принадлежит: Shandong University

The present invention declares a kind of compound to treat respiratory syncytial virus infection and its preparation method and application. The compound stated is cyclopamine's chemical analogs, has the property of inhibiting respiratory syncytial virus replication, and does not have the property of inhibiting Hedgehog signaling pathways. The preparation method stated is to get the cyclopamine's chemical analogs through drug chemical synthesis, then to screen the analogs with two parallel in vitro experiment. The compound described can be used to treat respiratory virus infection, paramyxovirus, respiratory syncytial virus infection, capillary bronchitis/pneumonia/tympanitis caused by respiratory syncytial virus. Furthermore, the compound described never cause the side effects of fetal malformation, and it overcame the teratogenicity of cyclopamine, and filled the gap of anti-human respiratory syncytial virus drug, especially of the field of pediatric drug. 113-. (canceled)15. The compound described in claim 14 , whose character is that the preparation protocol is as following:1) Preparation of intermediatesFirstly, Cyclopamine (498.06 mg, 1.21 mmol, 1.00 eq) and Et3N (489.76 mg, 4.84 mmol, 4.00 eq) were dissolved in dry DCM (4 ml);Secondly, TFAA (762.41 mg, 3.63 mmol, 3.00 eq) in DCM (1 ml) was added at 0° C.;Thirdly, the reaction mixture was warmed slowly to 15° C. and stirred for another 16 h;{'sub': '3', 'Fourthly, LCMS showed started material was almost consumed completely. (Desired product RT=0.996 min, 25%; di-CFCO byproduct RT=1.125 min, 47%);'}Fifthly, the reaction mixture was concentrated and the residue was diluted with MeOH (15 ml);Sixthly, the resulted suspension was heated to 70° C. for 1 h;Seventhly, then the reaction mixture was cooled to 15° C.;Lastly, the undissolved solid was collected by filtration. Intermediate (346.00 mg, 681.60 μmol, 56.33% yield) was obtained as white solid;2) Preparation of compounds,Firstly, 130.00 mg, 256.09 umol, 1.00 eq ...

Подробнее
23-05-2019 дата публикации

Complex and structurally diverse compounds

Номер: US20190152891A1
Принадлежит: University of Illinois

The invention provides a novel, general, and facile strategy for the creation of small molecules with high structural and stereochemical complexity. Aspects of the methods include ring system distortion reactions that are systematically applied to rapidly convert readily available natural products to structurally complex compounds with diverse molecular architectures. Through evaluation of chemical properties including fraction of sp 3 carbons, ClogP, and the number of stereogenic centers, these compounds are shown to be significantly more complex and diverse than those in standard screening collections. This approach is demonstrated with natural products (gibberellic acid, adrenosterone, and quinine) from three different structural classes, and methods are described for the application of this strategy to any suitable natural product.

Подробнее
16-06-2016 дата публикации

Isolation of Cyclopamine

Номер: US20160168193A1
Принадлежит:

Provided are deglycosylation methods designed to optimize the yield of a alkaloid from plant material and/or from an extract of plant material. 1VeratrumVeratrum. A method of isolating a deglycosylated alkaloid from plant material , comprising the steps of:{'i': Veratrum', 'Veratrum, '(i) providing a plant material comprising a glycosylated alkaloid selected from cycloposine or veratrosine;'}{'i': 'Veratrum', '(ii) prior to an extracting step, contacting the plant material with an aqueous solution at a pH between 5 and 7.5, the aqueous solution comprising greater than 25% water and at a temperature between 0° to 60° C.; and'}{'i': Veratrum', 'Veratrum', 'Veratrum, '(iii) extracting the plant material with an organic solvent optionally mixed with water and/or a base, the organic solvent selected from the group consisting of methanol, ethanol, isopropanol, 2-butanol, n-butanol, acetone, methyl ethyl ketone, ethyl acetate, isopropyl acetate, dichloromethane, chloroform, anisole, benzene, toluene, xylenes, hexanes, heptanes, tetrahydrofuran, dioxane and diethyl ether, or a mixture of two or more of the foregoing, to provide an extract comprising the deglycosylated alkaloid, wherein the deglycosylated alkaloid is cyclopamine or veratramine.'}2. The method according to claim 1 , wherein the aqueous solution is buffered.3. The method according to claim 1 , wherein the aqueous solution is neutral.4. The method according to claim 1 , wherein the aqueous solution is 100% water.5VeratrumVeratrum. The method according to claim 1 , wherein the glycosylated alkaloid is cyloposine and the deglycosylated alkaloid is cyclopamine.6VeratrumVeratrum. The method according to claim 1 , wherein the glycosylated alkaloid is veratrosine and the deglycosylated alkaloid is veratramine.7. The method according to claim 1 , wherein the contacting step comprises contacting the plant material with the aqueous solution for at least 10 minutes.8Veratrum. The method according to claim 1 , wherein the ...

Подробнее
15-09-2016 дата публикации

THERAPEUTIC COMPOUNDS AND METHODS

Номер: US20160264616A1
Принадлежит: UNIVERSITY OF IOWA RESEARCH FOUNDATION

Regulator of G Protein Signaling (RGS) proteins modulate the complex signaling pathways elicited by G protein coupled receptor activation. Recent studies have implicated RGS proteins in the development and progression of multiple cancers. Provided herein are inhibitors of RGS17, compositions thereof and methods of treating diseases using the inhibitors. 2. The method of wherein the compound is the compound of formula I or a pharmaceutically acceptable salt thereof.3. The method of claim 1 , wherein Rand Rare each H.4. The method of claim 1 , wherein Ris —OH or —O(C-C)alkyl.5. (canceled)6. The method of claim 1 , wherein Ris —OH or —O(C-C)alkyl.7. (canceled)8. The method of claim 1 , wherein Ris —OH or —O(C-C)alkyl.9. (canceled)10. The method of claim 1 , wherein Ris phenyl substituted with one or more groups independently selected from halo claim 1 , (C-C)alkyl claim 1 , (C-C)haloalkyl claim 1 , —OH claim 1 , —O(C-C)alkyl or —O(C-C)haloalkyl.11. The method of claim 1 , wherein Ris phenyl substituted with one or more —OH.1213-. (canceled)15. The method of claim 1 , wherein the aberrant G protein signaling is caused by increased RGS activity.16. The method of claim 1 , wherein the aberrant G protein signaling is caused by overexpression of RGS proteins.17. The method of claim 1 , wherein the RGS protein is RGS17.18. A method of treating or preventing a disease or disorder mediated by overexpression of RGS17 comprising administering to a patient in need thereof and which patient overexpresses RGS17 a therapeutically effective amount of a compound of that inhibits the interaction of RGS17 and Gαo20. The method of claim 1 , wherein the disease or disorder is cancer or Parkinson's disease.21. (canceled)22. A pharmaceutical composition comprising a compound of formula I claim 1 , formula II claim 1 , formula III or formula IV or a pharmaceutically acceptable salt thereof claim 1 , as described in claim 1 , and a pharmaceutically acceptable carrier or excipient.23. The ...

Подробнее
04-12-2018 дата публикации

For antitumor compound and its preparation method and application

Номер: CN106866774B
Принадлежит: Guangxi Teachers College

本发明公开了一种用于抗肿瘤的化合物,该化合物为B‑降‑3‑肟基胆甾‑4‑烯‑6‑(4'‑苯基)缩胺硫脲,其化学式如式5所示: 或者该化合物为3‑氮杂‑4‑氧代‑6‑(2'‑(5'‑甲氨基)噻二唑)‑A‑同‑B‑降胆甾‑4a‑烯,其化学式如式6所示:

Подробнее
16-01-2019 дата публикации

METHOD OF OBTAINING (8R)-8,13-CYCLO-13,14-SECO-5β-PREGN-2-EN-6,14,20-TRIONE

Номер: RU2677344C2

FIELD: chemical industry. SUBSTANCE: invention relates to a method for producing (8R)-8,13-cyclo-13,14-seco-5β-pregn-2-en-6,14,20-trione of formula (1), wherein 2,3-O-mesylate of poststerone is irradiated with ultrasound (22 kHz, 20 W) in dimethylformamide solution in the presence of 12 equivalents of sodium iodide and 12 equivalents of zinc for 4 h followed by water treatment of the reaction mixture and isolation of the target product using silica gel column chromatography. (1). EFFECT: technical result: method for producing (8R)-8,13-cyclo-13,14-seco-5β-pregn-2-en-6,14,20-trione with high yield is developed. 1 cl, 1 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 677 344 C2 (51) МПК C07J 75/00 (2006.01) C07J 69/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК C07J 75/00 (2018.08); C07J 69/00 (2018.08) (21)(22) Заявка: 2017125195, 13.07.2017 (24) Дата начала отсчета срока действия патента: Дата регистрации: 16.01.2019 (43) Дата публикации заявки: 15.01.2019 Бюл. № 2 (56) Список документов, цитированных в отчете о поиске: Y. Miyataet al. "Ecdysteroid from (45) Опубликовано: 16.01.2019 Бюл. № 2 C 2 2 6 7 7 3 4 4 (54) СПОСОБ ПОЛУЧЕНИЯ (8R)-8,13-ЦИКЛО-13,14-СЕКО-5β-ПРЕГН-2-ЕН-6,14,20-ТРИОНА (57) Реферат: Изобретение относится к способу получения получения (8R)-8,13-цикло-13,14-секо-5β-прегн(8R)-8,13-цикло-13,14-секо-5β-прегн-2-ен-6,14,202-ен-6,14,20-триона с высоким выходом. 1 пр. триона формулы (1), в котором 2,3-O-мезилат постстерона облучают ультразвуком (22 кГц, 20 Вт) в растворе диметилформамида в присутствии 12 эквивалентов йодистого натрия и 12 эквивалентов цинка в течение 4 ч с последующей водной обработкой реакционной смеси и выделением целевого продукта с помощью колоночной хроматографии на силикагеле. Технический результат: разработан способ (56) (продолжение): 13(14→8)абео-стероидов" Журнал органической химии, т.49, вып.12, 2013, 1781-1786. L. Canonica et al. "75. Fe(II)-Induced Fragmentation ...

Подробнее
31-03-1964 дата публикации

New drug, in particular for the treatment of protein anabolic disorders.

Номер: FR2963M
Автор:
Принадлежит: Roussel Uclaf SA

Подробнее
08-04-1966 дата публикации

Process for the preparation of 7a-methyl-alpha-n or-beta-homo-steroids

Номер: FR1434474A
Автор:
Принадлежит: Ciba AG, Ciba Geigy AG

Подробнее
27-10-1967 дата публикации

New 5, 10-seco-5, 19 Androstane and Pregnane Series Cyclosteroids and Methods of Preparation

Номер: FR1499110A
Автор:
Принадлежит: Roche Palo Alto LLC

Подробнее
30-12-1966 дата публикации

A-nor-b-homo-steroids dehydrogenation process

Номер: FR1463811A
Автор:
Принадлежит: Ciba AG, Ciba Geigy AG

Подробнее
08-01-1962 дата публикации

Method of irradiating steroids-dienes

Номер: FR1280563A
Автор:
Принадлежит: Ciba AG, Ciba Geigy AG

Подробнее
28-08-1964 дата публикации

New a-nor b-homo steroids and their production process

Номер: FR1370565A
Автор:
Принадлежит: Roussel Uclaf SA

Подробнее
27-11-1969 дата публикации

Process for the dehydration of A-nor-B homosteroids

Номер: DE1518627A1
Принадлежит: Ciba AG, Ciba Geigy AG

Подробнее
17-11-1971 дата публикации

Improvements in or relating to 5,10-seco-19-norandrostenes

Номер: GB1253925A
Автор:
Принадлежит: Roche Palo Alto LLC

1,253,925. 5,10 - Seco - 5,10 - (methylene, dihalomethylene or oxa)steroids. SYNTEX CORP. 12 Feb., 1969 [18 March, 1968], No. 7613/96. Headings C2C and C2U. Novel compounds of the formulµ (wherein X is CH 2 , CF 2 , CCl 2 or O; R is H, acyloxy, C 1-6 alkoxy, cyclopentyloxy, -cyclohexyloxy, tetrahydropyranyloxy or tetrahydrofuranyloxy; R<SP>1</SP> is CH 3 or C 2 H 5 ; R<SP>2</SP> is OH, acyloxy, tetrahydropyranyloxy or tetrahydrofuranyloxy; and R<SP>3</SP> is H, alkyl, alkenyl, alkynyl, haloalkynyl, cyclopropyl, dichloro- or difluorocyclopropyl, propadienyl, or dichloro- or difluoro-cyclopropenyl; or R<SP>2</SP>+R<SP>3</SP> is =O; R<SP>11</SP> is C 1-6 alkyl, cyclopentyl, cyclohexyl, acyl, tetrahydropyranyl or tetrahydrofuranyl; and X<SP>1</SP> is CH 2 , CF 2 or CCl 2 ) are prepared by the following reaction sequences (I) # (II) is effected with an alkali metal in liquid ammonia, (II) # (III) is effected with a per-acid to give (III) wherein X is O, or with a dihalocarbene generated from sodium trichloroacetate or chlorodifluoroacetate to give (III) wherein X is CCl 2 and CF 2 , respectively, (III) wherein X is CH 2 being prepared by treatment of the 5,10-dichloromethylene compound with Na or Li in 1.NH 3 and a lower alcohol or with LiAlH 4 , (IV) # (V) is effected with a base, e.g. an alkali metal hydroxide or alkoxide; (R<SP>1</SP> is C 1-6 alkyl). (VI) # (VII) is effected with cupric bromide, and the subsequent dehydrobromination by treatment with an alkali halide and alkali or alkaline earth metal carbonate or bicarbonate; (VIII) # (IX)is enolacylation or enol-alkylation and the products may be converted to the corresponding tetrahydropyranyl and tetrahydrofuranyl ethers by standard procedures. (IX) # (X) is effected directly using a Pd catalyst, 2,3-dichloro-5,6- dicyano - 1,4 - benzoquinone or N - bromosuccinimide or indirectly via a 7,8-dibromo derivative; (VI<SP ...

Подробнее
27-11-2003 дата публикации

Immunomodulating saponins, a method for their preparation and their use for vaccines

Номер: WO2003040163A3

The present invention relates to new saponins for increasing the immune response in mammals and finds application in the field of immunology, supplying in particular new adjuvants, obtained by hemi-synthesis, starting from terpene sources. It also embraces the methods for the use of the new saponins as adjuvants to increase the immune response to an antigen in a mammal. The saponins of the present invention are suitable for veterinary and human pharmaceutical compositions which include one or more antigens, in particular those of synthetic origin, and one or more diluents, in pharmaceutically acceptable vehicles. These compositions can be used as immunopotenciators and/or immunomodulators in animals and human beings. The present invention further constitutes a vaccination method that includes the administration of one or more antigens and one or optionally more than one hemi-synthetic saponin of the invention.

Подробнее
03-10-2005 дата публикации

New drug in particular for the treatment of disorders of protein anabolism.

Номер: FR1780M
Автор:
Принадлежит: Roussel Uclaf SA

Подробнее
07-01-2010 дата публикации

Methods for obtaining cyclopamine

Номер: CA2727986A1
Принадлежит: RADIENT TECHNOLOGIES Inc

The present invention relates to a process for extracting, purifying and isolating cyclopamine from cyclopamine-containing biomass comprising the steps of contacting cyclopamine-containing organic matter with an extractant (e.g., aqueous extractant) capable of extracting cyclopamine, separating the extracted organic matter from the cyclopamine/extract solution, concentrating the cyclopamine/extract solution leaving a concentrated aqueous solution, contacting the concentrated aqueous solution with an organic extractant capable of selectively extracting cyclopamine from the aqueous phase, concentrating the cyclopamine--containing organic phase, providing an enriched extract containing cyclopamine, separating cyclopamine from the enriched extract using column chromatography, providing at least one fraction containing cyclopamine, and crystallizing select chromatography fractions to provide purified cyclopamine.

Подробнее
20-05-1966 дата публикации

New alpha-nor beta-homo steroids and their production process

Номер: FR86951E
Автор:
Принадлежит: Roussel Uclaf SA

Подробнее
27-07-1964 дата публикации

New a-nor-b-homo-steroids which can be used in therapy, in particular as anti-inflammatory agents.

Номер: FR2692M
Автор:
Принадлежит: Ciba AG, Ciba Geigy AG

Подробнее
07-01-2010 дата публикации

Isolation of Cyclopamine

Номер: US20100003728A1

Provided are deglycosylation methods designed to optimize the yield of Veratrum alkaloid from Veratrum plant material and/or from an extract of Veratrum plant material.

Подробнее
25-04-1972 дата публикации

5 10-seco-19-norandrostenes

Номер: US3658916A
Принадлежит: Roche Palo Alto LLC

NEW 5,10-SECO-19-NORANDROSTENES PREPARED FROM ESTRA1,3,5(10),6.8-PENTAENES HAVING ESTROGENIC ACTIVITY.

Подробнее
15-05-1966 дата публикации

Process for the production of new 3,6-Dioxo-A-nor-B-homo-steroids

Номер: CH412876A
Принадлежит: Ciba Geigy

Подробнее
12-01-1968 дата публикации

Process for the preparation of new 19-nor-steroids

Номер: FR1509701A
Автор:
Принадлежит: Ciba AG, Ciba Geigy AG

Подробнее
05-08-1969 дата публикации

Process for dehydrogenating a-nor-b-homo-steroids

Номер: US3459791A
Принадлежит: Ciba Geigy Corp

Подробнее
20-10-2015 дата публикации

cyclopamine isolation

Номер: BRPI0913997A2
Принадлежит: Infinity Discovery Inc

Подробнее
23-02-1971 дата публикации

7alpha-difluoromethyl-a-nor-b-homo steroids and their preparation

Номер: US3565918A
Автор: John H Fried
Принадлежит: Roche Palo Alto LLC

THE PRESENT DISCLOSURE RELATES TO 3,5-DIOXO-7A-DIFFLUOROMETHYL-A-NOR-B-HOMO ANDROSTANES AND 19-NORANDROSTANES AND DERIVATIVES THEREOF WHERIN THE C-17B POSITION IS ELABORATED WITH A HYDROXYL, TETRAHYDROFURAN - 2 - YLOXY, TETRAHYDROPRAN - 2 - YLOXY OR HYDROCARBON CARBOXYLIC ACYLOXY GROUP OF LESS THAN 12 CARBON ATOMS, AND THE C17A POSITION WITH A HYDROGEN, (LOWER)ALKYL, (LOWER)ALKENYL, (LOWER)ALKYNYL OR HALO(LOWER)ALKYNYL GROUP. THESE COMPOUNDS ARE USEFUL AS ANABOLIC AND ANDROGENIC AGENTS. THOSE COMPOUNDS WHICH BEAR A 17A-ETHYNYL OR -HALOETHYNYL GROUPING ARE ADITIONALLY USEFUL AS PROGRESTATIONAL AGENTS. ALSO TAUGHT IS A METHOD FOR THE PREPARATION OF THESE COMPOUNDS.

Подробнее
19-12-1962 дата публикации

New A-nor B-homo 6-oxo steroids and their production process

Номер: BE619131A
Автор:
Принадлежит: Roussel Uclaf

Подробнее
14-08-1964 дата публикации

New a-nor b-homo steroids and their production process

Номер: FR1369321A
Принадлежит: Roussel Uclaf SA

Подробнее
06-08-1964 дата публикации

New fused polycyclic hydrocarbon derivatives and processes for their production

Номер: GB965714A
Автор:
Принадлежит: Roussel Uclaf SA

The invention comprises A-nor-B-homo-10#x-estrane compounds having the formula: <FORM:0965714/C1/1> (wherein R1 is hydrogen or an acyl radical derived from a lower organic acid, and R2 is hydrogen or a lower alkyl group having from 1 to 4 carbon atoms, as well as the enol esters derived from carboxylic acids of the compounds of the specified general formula in which R2 is hydrogen and processes for the preparation thereof by subjecting a 17b -acyloxy-A-nor-B-homo-estr-5(10)-ene-3 6-dione having the formula: <FORM:0965714/C1/2> (wherein R is an acyl radical derived from a lower organic acid) to reduction by an alkali metal borohydride in an acidic medium so as to selectively saturate the 5(10)-double bond thus yielding the corresponding 17b -acyloxy-A-nor-B-homo-5#x, 10#x-estrane-3, 6-dione, if desired saponifying this compound to obtain the corresponding 17b -hydroxy compound, or alternatively if desired treating with an alkylating agent in the presence of a basic condensation catalyst so as to form the corresponding 17b -hydroxy or 17b -acyloxy-5#x-lower alkyl-A-nor-B-homo-10#x-estrane -3, 6-dione. Reduction may be effected with alkali metal borohydride, e.g. potassium borohydride, and the alkylation may be effected with an alkyl iodide. Specification 965,712 is referred to.

Подробнее
12-04-1966 дата публикации

5, 10-seco-5, 19-cyclo-10-fluoro-steroids

Номер: US3246037A
Автор: Lawrence H Knox
Принадлежит: Roche Palo Alto LLC

Подробнее
11-02-1963 дата публикации

New drug especially for the treatment of disorders due to insufficiency of the corpus luteum.

Номер: FR1692M
Автор:
Принадлежит: Roussel Uclaf SA

Подробнее
27-07-1964 дата публикации

New a-nor-b-homo-steroids which can be used in therapy, in particular as gestagenes.

Номер: FR2691M
Автор:
Принадлежит: Ciba AG, Ciba Geigy AG

Подробнее
06-05-1966 дата публикации

Process for the preparation of new alpha-nor-beta-homo-steroids

Номер: FR87457E
Автор:
Принадлежит: Ciba AG, Ciba Geigy AG

Подробнее
05-08-1969 дата публикации

3-amino-a-nor-b-homo-steroids

Номер: US3459769A
Принадлежит: Ciba Geigy Corp

Подробнее
22-03-2022 дата публикации

一种烯丙醇胺甲酸酯类化合物的烯基化产物及其合成方法

Номер: CN110642752B
Принадлежит: Hangzhou Normal University

本发明公开了一种烯丙醇胺甲酸酯类化合物的烯基化产物及其合成方法,属于有机合成领域,该合成方法以烯丙醇或环己烯3‑醇类化合物为原料,利用钯催化体系,实现烯基同碳位烯基碳氢键的选择性切断和烯基化,有效合成烯丙醇胺甲酸酯类化合物。本发明所提供的合成方法首次实现了烯丙醇胺甲酸酯的选择性烯基化反应,合成效率高,对环境友好,生产环保压力小,原料经济易得,底物适用范围广泛,对环状和非环状的底物都适合,产率达到45~98%,应用范围广泛;本发明所提供的合成方法,适用于对结构较为复杂的具有特殊生物活性化合物的高效化学修饰,具有广泛的应用前景,在天然产物的合成方法上是一种有效补充。

Подробнее
04-07-2023 дата публикации

一种抗肿瘤化合物、其制备方法、药物组合物及应用

Номер: CN116375789A
Автор: 张宁, 徐红闯, 杨兴, 杨慧

本发明提供了一种抗肿瘤化合物、其制备方法、药物组合物及应用。还提供了该抗肿瘤化合物的制备方法、药物组合物和应用。本发明首次将仑伐替尼和藜芦胺进行连接,合成一类新化合物,首次证实了该新化合物在动物模型中治疗肝癌的效果优于仑伐替尼。且本发明的抗肿瘤化合物优于仑伐替尼的新化合物,提升了原发性肝癌的治疗效果。

Подробнее
16-03-1963 дата публикации

Procedimiento de preparación de los 17-beta-or a-nor b-homo isoxazolo (3,5,6,d) delta-10 xi-estrenos

Номер: ES281945A1
Автор:
Принадлежит: Roussel Uclaf SA

Подробнее
03-08-1965 дата публикации

A-nor-b-homo-steroids having isoxazole substituent and process of preparation

Номер: US3198805A
Принадлежит: Roussel Uclaf SA

Подробнее
21-08-1964 дата публикации

Dérivés stéroïdes à cycles modifiés et substituants hétérocycliques et procédé de préparation

Номер: FR1369968A
Автор:
Принадлежит: Roussel Uclaf SA

Подробнее
15-12-2011 дата публикации

Steroid-Derived Cyclopamine Analogs and Methods for Using the Same in the Prevention or Treatment of Cancer

Номер: US20110306662A1
Принадлежит: Wistar Institute of Anatomy and Biology

The present invention relates to steroid-derived cyclopamine analogs and methods for using the same for inhibiting sonic hedgehog signaling and preventing or treating cancer. A method for synthesizing the analogs of the present invention from a steroid is also provided.

Подробнее
20-12-1977 дата публикации

3-Alkoxy-D-homo-C-nor-13α, 14α-gona-1,3,5,(10),6,8-pentaen-17-one and derivatives thereof

Номер: US4064177A
Автор: Richard M. Weier
Принадлежит: GD Searle LLC

The present invention relates to 3-alkoxy-D-homo-C-nor-13α,14α-gona-1,3,5(10),6,8-pentaen-17-one and certain derivatives thereof. The compounds of this invention display valuable pharmacological activities, such as antispasmodic utility.

Подробнее
31-08-1967 дата публикации

Verfahren zur Herstellung von 3,6-Dioxo-A-nor-B-homo-steroiden

Номер: CH442290A
Принадлежит: Ciba Geigy

Подробнее
14-11-2023 дата публикации

一种藜芦胺类化合物、其制备方法及其应用

Номер: CN117050136A

本发明公开了一种藜芦胺类化合物、其制备方法及其应用。本发明提供了一种如式I所示的藜芦胺类化合物,可作为一系列新型AP‑1抑制剂并用于制备相应的疾病的药物。在初步活性研究中显示本发明提供的化合物具有很强的抑制肿瘤细胞增殖活性;具有制备成为新型抗肿瘤药物的潜力,具有较好的市场化前景。

Подробнее
03-11-1964 дата публикации

Dehydro derivatives of d-homo-c-norestranes and intermediates thereto

Номер: US3155729A
Автор: William F Johns
Принадлежит: GD Searle LLC

Подробнее
22-04-1971 дата публикации

Neue 3-Oxo-A-nor-B-homo-pregnadiene und ein Verfahren zu deren Herstellung

Номер: DE1768273A1
Принадлежит: Ciba Geigy AG

Подробнее
15-12-1967 дата публикации

Verfahren zur Darstellung neuer A-nor-B-homo-steroide

Номер: CH448075A
Принадлежит: Ciba Geigy

Подробнее
14-03-1966 дата публикации

[UNK]

Номер: FR4002M
Автор:
Принадлежит:

Подробнее
30-04-1966 дата публикации

Procédé de préparation de nouveaux dérivés stéroïdes, à structure modifiée

Номер: CH411869A
Принадлежит: Roussel Uclaf

Подробнее
24-04-1967 дата публикации

[UNK]

Номер: FR5028M
Автор:
Принадлежит:

Подробнее
13-05-1966 дата публикации

[UNK]

Номер: NL6514667A
Автор:
Принадлежит:

Подробнее
22-05-1967 дата публикации

[UNK]

Номер: FR5102M
Автор:
Принадлежит:

Подробнее
01-04-1965 дата публикации

[UNK]

Номер: BE672157A
Автор:
Принадлежит:

Подробнее
10-12-1968 дата публикации

Verfahren zur Herstellung von neuen 3-Amino-steroiden

Номер: AT267085B
Автор:
Принадлежит: Ciba Geigy

Подробнее
12-12-1961 дата публикации

New steroid compounds and process for their manufacture

Номер: US3013027A
Принадлежит: CIBA PHARM PROD Inc

Подробнее
25-05-1970 дата публикации

[UNK]

Номер: FR7943M
Автор:
Принадлежит:

Подробнее
04-11-1968 дата публикации

[UNK]

Номер: NL6806233A
Автор:
Принадлежит:

Подробнее
17-04-1970 дата публикации

[UNK]

Номер: FR1588479A
Автор:
Принадлежит:

Подробнее
04-11-1968 дата публикации

[UNK]

Номер: BE714558A
Автор:
Принадлежит:

Подробнее
07-12-1971 дата публикации

A 3-oxo-a-nor-b-homo-pregnadienes and a process for their manufacture

Номер: US3625997A
Принадлежит: Ciba Geigy Corp

Compounds of the formula FOR EXAMPLE: 3,20-DIOXO-11 Beta ,17-DIHYDROXY-21-ACETOXY-A-norB-homo-pregna-1,5-diene or 3,11,20-trioxo-17-hydroxy-21-acetoxyA-nor-B-homo-pregna-1,5,7-triene. Use: anti-inflammatory agents.

Подробнее
17-05-1971 дата публикации

[UNK]

Номер: SE335121B
Автор: K Schaffner, O Jeger
Принадлежит: Ciba Geigy AG

Подробнее
13-11-1969 дата публикации

Verfahren zur Darstellung eines neuen A-Nor-B-homo-steroids

Номер: DE1443650A1
Принадлежит: Ciba AG, Ciba Geigy AG

Подробнее
11-02-1965 дата публикации

[UNK]

Номер: BE650730A
Автор:
Принадлежит:

Подробнее
30-08-1971 дата публикации

[UNK]

Номер: SE338044B
Автор: K Schaffner, O Jaeger
Принадлежит: Ciba Geigy AG

Подробнее
26-07-1965 дата публикации

[UNK]

Номер: NL6408227A
Автор:
Принадлежит:

Подробнее
14-09-1967 дата публикации

[UNK]

Номер: BE650731A
Автор:
Принадлежит:

Подробнее
31-10-1967 дата публикации

Verfahren zur Darstellung neuer A-nor-B-homosteroide

Номер: CH445482A
Принадлежит: Ciba Geigy

Подробнее
07-05-1962 дата публикации

Nouveaux stéroïdes à cycles modifiés et procédé de préparation

Номер: BE610047A
Автор:
Принадлежит: Chimiotherapie Lab Franc

Подробнее
17-07-1964 дата публикации

Nouveaux stéroïdes à cycles modifiés et procédé de préparation

Номер: FR1366719A
Автор:
Принадлежит: Roussel Uclaf SA

Подробнее
05-10-2020 дата публикации

3β-Hydroksy-17a-oksa-D-homo-B-norandrost-5-en-17-on i sposób wytwarzania 3β-hydroksy-17a-oksa-D-homo-B-norandrost-5-en-17-onu

Номер: PL429380A1
Принадлежит: UNIWERSYTET PRZYRODNICZY WE WROCLAWIU

Wynalazek dotyczy 3ß-hydroksy-17a-oksa-D-homo-B-norandrost-5-en-17-onu i sposobu wytwarzania 3ß-hydroksy-17a-oksa-D-homo-B-norandrost-5-en-17-onu. Postępując zgodnie z wynalazkiem, w wyniku działania układu enzymatycznego zawartego w komórkach szczepu Beauvera bassiana KCH1065 na octan B-nor-dehydroepiandrosteronu, o wzorze 1, następuje hydroliza wiązania estrowego oraz utlenienie typu Baeyera-Villigera grupy karbonylowej substratu do laktonu, o wzorze 2. Uzyskany w ten sposób produkt wydziela się z wodnej kultury mikroorganizmu, znanym sposobem, przez ekstrakcję rozpuszczalnikiem organicznym niemieszającym się z wodą (chloroform) i oczyszcza chromatograficznie.

Подробнее
18-12-1969 дата публикации

Verfahren zur Herstellung von 7alpha-beta-Methyl-A-nor-B-homo-steroide

Номер: DE1518637A1
Принадлежит: Ciba AG, Ciba Geigy AG

Подробнее
03-05-1965 дата публикации

[UNK]

Номер: NL6412652A
Автор:
Принадлежит:

Подробнее
16-04-1965 дата публикации

Procedimiento para la fabricacion de a-nor-b-homo-esteroides

Номер: ES305489A1
Автор:
Принадлежит: Ciba AG, Ciba Geigy AG

Подробнее
17-09-1964 дата публикации

[UNK]

Номер: BE655087A
Автор:
Принадлежит:

Подробнее
30-01-1964 дата публикации

Verfahren zur Herstellung von A-nor-B-homo-í¸-oestrenverbindungen

Номер: DE1161887B
Принадлежит: Roussel Uclaf SA

Подробнее
27-09-1965 дата публикации

[UNK]

Номер: NL6503746A
Автор:
Принадлежит:

Подробнее
13-02-1965 дата публикации

[UNK]

Номер: BE661552A
Автор:
Принадлежит:

Подробнее
14-08-1964 дата публикации

Nouveaux a-nor b-homo stéroïdes et leur obtention

Номер: FR1369320A
Автор:
Принадлежит: Roussel Uclaf SA

Подробнее
28-05-1968 дата публикации

A-nor-d-homosteroids

Номер: US3385883A
Автор: Seymour D Levine
Принадлежит: ER Squibb and Sons LLC

Подробнее
15-12-1999 дата публикации

A环被修饰的积雪草酸衍生物

Номер: CN1238755A
Принадлежит: Dong Kook Pharmaceutical Co Ltd

本发明涉及式1表示的A环被修饰的积雪草酸衍生物,及含上述衍生物作为活性组分的抗癌剂和肝功能保护剂。

Подробнее
12-09-2023 дата публикации

一种藜芦胺类化合物、其制备方法及其应用

Номер: CN113929614B

本发明公开了一种藜芦胺类化合物、其制备方法及其应用。本发明提供了一种如式I所示的藜芦胺类化合物,可作为一系列新型AP‑1抑制剂并用于制备相应的疾病的药物。在初步活性研究中显示本发明提供的化合物具有很强的抑制肿瘤细胞增殖活性;具有制备成为新型抗肿瘤药物的潜力,具有较好的市场化前景。

Подробнее
07-09-2021 дата публикации

Crystal forms of an antitumor agent and their preparation methods

Номер: US11111267B2
Автор: Xianchang Gong
Принадлежит: Individual

The present invention provides two crystal forms of jervine and their preparation methods, and their application as antitumor agents. The preparation methods of these two crystal forms are simple, high yield and can be easily scaled to industry scale.

Подробнее